Of interest, a small number of clinical trials have targeted ACVR2 signalling in cachectic conditions associated with pancreatic and lung cancer (NCT01433263; NCT01505530) in an attempt to preserve lean body mass, however with minimal success. Here, ACVR2A is linked to lung cancer.